Other
PTCL
0
Pipeline Programs↗
4
Active Trials↗
2
Companies Involved↗
PTCL is an early-stage landscape with 0 programs across 2 companies. The most active players are Dizal Pharmaceuticals, Boryung Pharmaceutical Co., Ltd.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
7
clinical trials
Recruiting2 · 29%
Withdrawn2 · 29%
Not yet recruiting2 · 29%
Unknown status1 · 14%
Clinical Trials
Trial Activity
7 trials
Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL
Withdrawn·—·Phase 3·NCT03355768
Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL
Withdrawn·—·Phase 1·NCT02757248
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)